Drugs

FDA-483 Response Can Influence Future Agency Action: Post

Consulting firm NSF says that how a company responds to a form FDA-483 can influence how inspection findings are classified and what steps the agency might take in the future. The firm uses an online post (includes a link to the webinar) to present the lessons learned from a webinar it held that featured two former FDAers.

The post says the webinar’s key takeaways were:

aim to respond within 15 business days;
focus on root cause and not only corrections;
assess potential system-wide impact;
provide clear, evidence-based corrective and preventive action plans; and
ensure management oversight and accountability.

Companies often err, the post says, by overestimating the strength of their quality management systems. “It is common,” it says, “to assume that minor deficiencies can be addressed later, or that a high-level response will be sufficient.” In practice, it says, responses that lack depth or specificity can raise additional questions. “A narrow focus on individual observations, without considering how they relate to broader processes, often leads to corrective actions that do not address underlying risk,” the authors say.

The post reviews an FDA March draft guidance on responding to FDA-483 observations that provides greater clarity on what is expected in a response. It says a strong form 483 response is structured, comprehensive, and supported by evidence. It clearly addresses each inspection observation while demonstrating an understanding of both the immediate issue and any broader system impact. Effective responses, it concludes, include detailed investigation findings, clearly defined corrective and preventive action plans, and appropriate management oversight.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome